27 April 2012
LSE: VER
Vernalis plc
Admission of Shares to AIM
With effect from 8:00 a.m. today, Vernalis'
ordinary shares of 1 pence each ("Ordinary
Shares") will be admitted to trading on AIM and the
Company's listing on the premium segment of the
Official List and trading on the London Stock
Exchange's main market for listed securities will both
be cancelled.
At admission to AIM, there will be 442,112,768
Ordinary Shares in issue. The ISIN and ticker for the
Company's shares will continue to be GB00B3Y5L754 and
VER respectively.
Nomura Code Securities Limited will act as the
Company's Nominated Adviser (Nomad) pursuant to the AIM
rules.
Enquiries:
|
Vernalis
|
+44 (0) 118 938 0015
|
|
Ian Garland, Chief Executive Officer
David Mackney, Chief Financial Officer
|
|
|
Nomura Code Securities
|
+44 (0) 20 7776 1200
|
|
Jonathan Senior, Giles
Balleny
|
|
|
Brunswick Group
|
+44 (0) 20 7404 5959
|
|
Jon Coles, Kristin Shine
|
|
|
Taylor Rafferty
|
+44 (0) 20 7614 2900
|
|
Rob Newman, Faisal Kanth
|
|
Notes to Editors
About Vernalis
Vernalis is a revenue generating development stage
pharmaceutical company with significant expertise in drug
development. The Group has one marketed product,
frovatriptan for the acute treatment of migraine, an
exclusive licensing agreement to develop and commercialise
multiple novel products focussed on the US prescription
cough/cold market as well as eight programmes in its NCE
development pipeline. Vernalis has significant
expertise in fragment and structure based drug discovery
which it leverages to enter into collaborations with larger
pharmaceutical companies. The Company's
technologies, capabilities and products are endorsed by
collaborations with Endo, Genentech, GSK, Lundbeck,
Menarini, Novartis, Servier and Tris.
For further information about Vernalis, please
visit www.vernalis.com
Vernalis Forward-Looking Statement
This news release may contain forward-looking
statements that reflect the Company's current
expectations regarding future events including the clinical
development and regulatory clearance of the Company's
products, the Company's ability to find partners for
the development and commercialisation of its products, as
well as the Company's future capital raising
activities. Forward-looking statements involve risks and
uncertainties. Actual events could differ materially from
those projected herein and depend on a number of factors
including the success of the Company's research
strategies, the applicability of the discoveries made
therein, the successful and timely completion of clinical
studies, the uncertainties related to the regulatory
process, the ability of the Company to identify and agree
beneficial terms with suitable partners for the
commercialisation and/or development of its products, as
well as the achievement of expected synergies from such
transactions, the acceptance of frovatriptan and other
products by consumers and medical professionals, the
successful integration of completed mergers and
acquisitions and achievement of expected synergies from
such transactions, and the ability of the Company to
identify and consummate suitable strategic and business
combination transactions.
Recommend:
